TALAPRO-2 Trial: First-line talazoparib plus enzalutamide VS placebo plus enzalutamide in prostate cancer – Mirrors of Medicine
Mirrors of Medicine shared a post on X:
“First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant Prostate Cancer and homologous recombination repair gene alterations: TALAPRO-2
Study finds the combination of talazoparib and enzalutamide not only significantly improved radiographic progression-free survival but also delayed patient-reported deterioration in quality of life, urinary symptoms, and pain in men with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC).
Among 399 patients evaluated, those receiving talazoparib plus enzalutamide experienced longer median times to deterioration in global health status/quality of life (27.1 vs. 19.3 months; HR 0.69, *p*=0.032) and urinary symptoms (HR 0.56, *p*=0.022) compared to placebo plus enzalutamide.
Although differences in symptom scores and functioning did not consistently reach thresholds for clinical meaningfulness, trends favored the talazoparib combination across multiple patient-reported outcome measures, suggesting added benefit in preserving quality of life in this population.”
Authors: Andre P Fay et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023